Innate Pharma shares surged 13% premarket after the FDA cleared a confirmatory late-stage trial of its drug Lacutamab for rare skin cancers, including Sezary syndrome and Mycosis fungoides. The study, set to begin in early 2026, aims to measure progression-free survival, with the FDA raising no additional protocol concerns.